跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AB-21
首页
药物
AB-21
AB-21
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Human monoclonal anti-amyloid-beta antibodies
申请人: UNIV MARBURG PHILIPPS
优先权: 2008
US
5 件公开
USE OF ANTI-NECTIN-4 ANTIBODY-DRUG CONJUGATE IN TREATING CANCER AND METHOD THEREFOR
申请人: MABWELL SHANGHAI BIOSCIENCE CO LTD
优先权: 2025
WO
CAR-T culture medium and application thereof
申请人: UNIV SOUTHEAST
优先权: 2024
CN
GLYR1 targeting antibody, preparation method thereof and application thereof in tumor prevention and treatment
申请人: SUZHOU INST OF SYSTEMS MEDICINE
优先权: 2025
CN
GLYR1 targeting antibody, preparation method thereof and application of GLYR1 targeting antibody in tumor prevention and treatment
申请人: SUZHOU INST OF SYSTEMS MEDICINE
优先权: 2025
CN
GLYR1 specific antibody as well as preparation method and application thereof in tumor prevention and treatment
申请人: SUZHOU INST OF SYSTEMS MEDICINE
优先权: 2025
CN
Vδ2T细胞的培养液及培养方法与应用
申请人: 深圳市先康达生命科学有限公司
优先权: 2025
CN
API specific biological immunotherapy
申请人: ZHAN LINA
优先权: 2016
CN
药物
反馈